Comprehensive clinical and laboratory follow-up of a female patient with Ebola virus disease: Sierra Leone Ebola virus persistence study

Sierra Leone Ebola Virus Persistence Study Group

doi:10.1093/ofid/ofz068

Comprehensive clinical and laboratory follow-up of a female patient with Ebola virus disease: Sierra Leone Ebola virus persistence study

Sierra Leone Ebola Virus Persistence Study Group

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

The clinical, virologic, and immunologic findings in a female Ebola virus disease patient are described. During the long-term follow-up, Ebola virus RNA was detectable in vaginal fluid before 36 days after symptom onset, with nearly an identical genome sequence as in acute phase blood. Ebola-specific T cells retained activation at 56 days after disease onset.

Original language	English
Article number	ofz068
Journal	Open Forum Infectious Diseases
Volume	6
Issue number	3
DOIs	https://doi.org/10.1093/ofid/ofz068
Publication status	Published - Mar 2019
Externally published	Yes

Bibliographical note

Funding Information:
work was supported by the World Health Organization, the United States Centers for Disease Control and Prevention, the Chinese Center for Disease Control and Prevention, the Paul G. Allen Family Foundation, and the Joint United Nations Program on HIV/AIDS, including the Major Special Projects for Infectious Disease Research of China (grant 2016ZX10004222-003). The WHO acknowledges the financial contribution of the WHO Ebola Response Program, the Paul G. Allen Family Foundation, and the United Nations Development Program (UNDP)- United Nations Population Fund (UNFPA)-UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored program executed by the WHO in support of the Sierra Leone Ebola Virus Persistence Study.

Publisher Copyright:
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence

Keywords

Clinical sequelae
Ebola virus
Immune responses
Virus genome
Virus persistence

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ofid/ofz068

Cite this

@article{307133120a18451196733d51107dfdec,

title = "Comprehensive clinical and laboratory follow-up of a female patient with Ebola virus disease: Sierra Leone Ebola virus persistence study",

abstract = "The clinical, virologic, and immunologic findings in a female Ebola virus disease patient are described. During the long-term follow-up, Ebola virus RNA was detectable in vaginal fluid before 36 days after symptom onset, with nearly an identical genome sequence as in acute phase blood. Ebola-specific T cells retained activation at 56 days after disease onset.",

keywords = "Clinical sequelae, Ebola virus, Immune responses, Virus genome, Virus persistence",

author = "{Sierra Leone Ebola Virus Persistence Study Group} and Liu, {William J.} and Sesay, {Foday R.} and Antoine Coursier and Barbara Knust and Marrinan, {Jaclyn E.} and Shannon Whitmer and McDonald, {Suzanna L.R.} and Philippe Gaillard and Yang Liu and Qiudong Su and Yong Zhang and Ian Crozier and Archchun Ariyarajah and Marylin Carino and Thomas Massaquoi and Nathalie Broutet and Wenbo Xu and Guizhen Wu and Ute Str{\"o}her and Gao, {George F.} and Pierre Formenty and Foday Sahr and Deen, {Gibrilla F.} and James Bangura and Amara Jambai and Faustine James and Alie Wurie and Francis Yamba and Halima Fornah and Richard Kamara and Massaquoi, {Thomas A.} and Tina Davies and Thorson, {Anna E.} and Florence Baingana and Durski, {Kara N.} and Ndema Habib and Lamunu, {Margaret O.} and Sihem Landoulsi and Dhamari Naidoo and Carmen Valle and Neetu Abad and Aneesah Akbar-Uqdah and Gail Bolan and Kyle Bernstein and Jeffrey Brock and Elizabeth Ervin and Rachel Kachur and Klena, {John D.} and Jill Huppert and Brandy Maddox",

note = "Funding Information: work was supported by the World Health Organization, the United States Centers for Disease Control and Prevention, the Chinese Center for Disease Control and Prevention, the Paul G. Allen Family Foundation, and the Joint United Nations Program on HIV/AIDS, including the Major Special Projects for Infectious Disease Research of China (grant 2016ZX10004222-003). The WHO acknowledges the financial contribution of the WHO Ebola Response Program, the Paul G. Allen Family Foundation, and the United Nations Development Program (UNDP)- United Nations Population Fund (UNFPA)-UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored program executed by the WHO in support of the Sierra Leone Ebola Virus Persistence Study. Publisher Copyright: {\textcopyright} The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence",

year = "2019",

month = mar,

doi = "10.1093/ofid/ofz068",

language = "English",

volume = "6",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

number = "3",

}

TY - JOUR

T1 - Comprehensive clinical and laboratory follow-up of a female patient with Ebola virus disease

T2 - Sierra Leone Ebola virus persistence study

AU - Sierra Leone Ebola Virus Persistence Study Group

AU - Liu, William J.

AU - Sesay, Foday R.

AU - Coursier, Antoine

AU - Knust, Barbara

AU - Marrinan, Jaclyn E.

AU - Whitmer, Shannon

AU - McDonald, Suzanna L.R.

AU - Gaillard, Philippe

AU - Liu, Yang

AU - Su, Qiudong

AU - Zhang, Yong

AU - Crozier, Ian

AU - Ariyarajah, Archchun

AU - Carino, Marylin

AU - Massaquoi, Thomas

AU - Broutet, Nathalie

AU - Xu, Wenbo

AU - Wu, Guizhen

AU - Ströher, Ute

AU - Gao, George F.

AU - Formenty, Pierre

AU - Sahr, Foday

AU - Deen, Gibrilla F.

AU - Bangura, James

AU - Jambai, Amara

AU - James, Faustine

AU - Wurie, Alie

AU - Yamba, Francis

AU - Fornah, Halima

AU - Kamara, Richard

AU - Massaquoi, Thomas A.

AU - Davies, Tina

AU - Thorson, Anna E.

AU - Baingana, Florence

AU - Durski, Kara N.

AU - Habib, Ndema

AU - Lamunu, Margaret O.

AU - Landoulsi, Sihem

AU - Naidoo, Dhamari

AU - Valle, Carmen

AU - Abad, Neetu

AU - Akbar-Uqdah, Aneesah

AU - Bolan, Gail

AU - Bernstein, Kyle

AU - Brock, Jeffrey

AU - Ervin, Elizabeth

AU - Kachur, Rachel

AU - Klena, John D.

AU - Huppert, Jill

AU - Maddox, Brandy

N1 - Funding Information: work was supported by the World Health Organization, the United States Centers for Disease Control and Prevention, the Chinese Center for Disease Control and Prevention, the Paul G. Allen Family Foundation, and the Joint United Nations Program on HIV/AIDS, including the Major Special Projects for Infectious Disease Research of China (grant 2016ZX10004222-003). The WHO acknowledges the financial contribution of the WHO Ebola Response Program, the Paul G. Allen Family Foundation, and the United Nations Development Program (UNDP)- United Nations Population Fund (UNFPA)-UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored program executed by the WHO in support of the Sierra Leone Ebola Virus Persistence Study. Publisher Copyright: © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence

PY - 2019/3

Y1 - 2019/3

N2 - The clinical, virologic, and immunologic findings in a female Ebola virus disease patient are described. During the long-term follow-up, Ebola virus RNA was detectable in vaginal fluid before 36 days after symptom onset, with nearly an identical genome sequence as in acute phase blood. Ebola-specific T cells retained activation at 56 days after disease onset.

AB - The clinical, virologic, and immunologic findings in a female Ebola virus disease patient are described. During the long-term follow-up, Ebola virus RNA was detectable in vaginal fluid before 36 days after symptom onset, with nearly an identical genome sequence as in acute phase blood. Ebola-specific T cells retained activation at 56 days after disease onset.

KW - Clinical sequelae

KW - Ebola virus

KW - Immune responses

KW - Virus genome

KW - Virus persistence

UR - http://www.scopus.com/inward/record.url?scp=85066405934&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofz068

DO - 10.1093/ofid/ofz068

M3 - Article

AN - SCOPUS:85066405934

VL - 6

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

SN - 2328-8957

IS - 3

M1 - ofz068

ER -

Comprehensive clinical and laboratory follow-up of a female patient with Ebola virus disease: Sierra Leone Ebola virus persistence study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this